Expert Groups

The primary objective of the expert working groups/centers of the IHBT is to coordinate patient treatment, manage clinical studies, clinical and laboratory research projects in patients with a given diagnosis at the diagnostic, therapeutic and research levels.

Working Group for AML
The AML Working Group oversees the diagnosis and treatment of patients with acute myeloid leukemia at the Institute of Hematology and Blood Transfusion. It provides a platform for connecting physicians from the clinical department and laboratory staff to discuss and efficiently share information regarding the diagnosis and treatment of individual patients. The group also closely collaborates with IHBT scientific teams, particularly in applied research in the field of AML and myeloid malignancies in general. Group members participate in the organization and conduct of clinical studies concerning AML at IHBT and, within clinical research and information sharing, also collaborate with other hematological centers in the Czech Republic and abroad. Group members also present their work results at professional hematological events in the Czech Republic and abroad and publish in international and domestic journals.
Clinical coordinator is MUDr. Jan Válka, Ph.D.  (jan.valka@uhkt.cz)

Working Group for ALL
Clinical coordinator is MUDr. Mgr. Cyril Šálek, Ph.D. (cyril.salek@uhkt.cz)

Working Group for CML
The CML Working Group addresses issues in patients with chronic myeloid leukemia. Whether it is precise diagnosis or therapy with all available treatment options. The complexity of care is only possible through intensive collaboration of physicians from the clinical department with laboratory staff as well as scientific teams from the research department, with the most intensive collaboration with a highly accredited facility – the department of molecular genetics. There is also intensive collaboration with other hematological care centers in the Czech Republic and throughout Europe on joint clinical and laboratory projects. Clinical studies concerning CML are also addressed, including the introduction of new drugs into clinical practice. Group members present their work results at professional hematological events in the Czech Republic and abroad as well as through publications in domestic and foreign journals.
Clinical coordinator MUDr. Hana Klamová, CSc. (hana.klamova@uhkt.cz)
Laboratory coordinator doc. Mgr. Kateřina Machová Poláková, Ph.D. (katerina.machova@uhkt.cz)

Working Group for Lymphoproliferative Disorders + CAR-T
Clinical coordinator is MUDr. Robert Pytlík, Ph.D. (robert.pytlik@uhkt.cz)

Working Group for MDS
The MDS Group co-organizes the activities of the national working group for MDS (Czech MDS Group), supports the activities of the patient association for MDS patients, conducts educational activities at national and international events.
Clinical coordinator of the group is MUDr. Markéta Šťastná Marková, CSc. (marketa.markova@uhkt.cz)

Working Group for Myeloproliferative Disorders
The working group for Ph- myeloproliferative disorders at the Institute of Hematology and Blood Transfusion (IHBT) specializes in the diagnosis and treatment of Ph-negative myeloproliferative disorders. These disorders include polycythemia vera, essential thrombocythemia and primary myelofibrosis. We also deal with the diagnosis and treatment of rare Ph- myeloproliferative disorders such as chronic neutrophilic leukemia and chronic eosinophilic leukemia and further myelodysplastic-myeloproliferative disorders (e.g. atypical chronic myeloid leukemia).
Within IHBT we provide comprehensive care to patients, which includes specialized diagnosis including molecular-genetic testing, individualized treatment using the most modern available procedures, the possibility of participation in clinical studies testing new therapeutic agents, regular monitoring of disease progression and treatment response, consultations for physicians from other facilities.
Our team closely collaborates with other specialists both within the Czech Myeloproliferative Working Group (CZEMP) and within the international Central European Myeloproliferative Neoplasm Organisation (CEMPO). We actively participate in research of these disorders and take part in international clinical studies. We are authors/co-authors of national guidelines for the diagnosis and treatment of these groups. We participate in undergraduate and postgraduate training of physicians.
For patients and their loved ones we offer comprehensive care at one facility, consultations with leading specialists in the field, access to the latest treatment options, supportive and palliative care.
Clinical coordinator is MUDr. Jindřích Polívka, MHA (jindrich.polivka@uhkt.cz)

Center for Diagnosis and Treatment of Rare Congenital and Acquired Disorders of the Red Blood Cell Series
The facility provides emergency and consultative care also for patients from other countries and various ethnic backgrounds given the high incidence of some congenital diseases of the red blood cell series in non-European regions as part of collaboration in the European Reference Network as the EuroBloodNet Center.
Responsible person is prof. MUDr. J. Čermák, CSc.. (jaroslav.cermak@uhkt.cz)

Center for Diagnosis and Treatment of Rare Hemostasis Disorders
Responsible person is MUDr. Peter Salaj. (peter.salaj@uhkt.cz)